This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LEXINGTON, Mass., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will present at the following upcoming conferences:
Stifel Nicolaus 2012 Healthcare Conference – Thursday, September 6, at 1:30 p.m. EDT in Boston. A corresponding webcast of this presentation can be accessed by visiting:
Dan Passeri, President and Chief Executive Officer, will provide an overview of Curis' development programs, including Erivedge™ (vismodegib), CUDC-101, CUDC-907 and Debio 0932, as well as discuss other corporate activities.
The presentations will be archived shortly after the live events and available for 30 days following the conferences. In addition, presentations will be available for 30 days on the Investor Relations section of the Curis website at
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at
The Curis, Inc. logo is available at
CONTACT: Michael P. Gray
CFO & COO